Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Cyclophosphamide + Fludarabine + Mycophenolate mofetil|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Cyclophosphamide||Cytoxan||CPM||Chemotherapy - Alkylating 14||Cytoxan (cyclophosphamide) is an alkylating agent, which inhibits DNA replication (NCI Drug Dictionary). Cytoxan (cyclophosphamide) is FDA approved in multiple hematological malignancies, breast cancer, neuroblastoma, ovarian cancer, and retinoblastoma (NCI Drug Dictionary).|
|Fludarabine||Fludara||FAMP|Fludarabine phosphate||Flurdara (fludarabine) is converted to 2-fluoro-ara-ATP intracellularly, which potentially inhibits DNA polymerase alpha, ribonucleotide reductase and DNA primase, leading to decreased DNA synthesis and reduced tumor growth (NCI Drug Dictionary)|
|Mycophenolate mofetil||Cellcept||RS-61443||Cellcept (mycophenolate mofetil) is metabolized to mycophenolic acid, which interferes with proliferation of B- and T-lymphocytes, resulting in immunosuppresion (PMID: 32228535).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT01203722||Phase Ib/II||Tacrolimus Sirolimus Cyclophosphamide + Fludarabine + Mycophenolate mofetil||Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies||Recruiting|
|NCT02423915||Phase Ib/II||Filgrastim Rituximab Cyclophosphamide + Fludarabine + Mycophenolate mofetil Sirolimus||Fucosylated T Cells for Graft Versus Host Disease (GVHD) Prevention||Active, not recruiting|
|NCT02722668||Phase II||Cyclophosphamide + Fludarabine + Mycophenolate mofetil Sirolimus anti-thymocyte globulin||UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep||Recruiting|